Massachusetts Financial Services Co. MA Purchases 312 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Massachusetts Financial Services Co. MA boosted its position in Twist Bioscience Co. (NASDAQ:TWST) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,279 shares of the company’s stock after acquiring an additional 312 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Twist Bioscience were worth $457,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. EdgeRock Capital LLC bought a new position in Twist Bioscience in the second quarter worth approximately $43,000. Blue Trust Inc. boosted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience in the second quarter worth approximately $61,000. Nisa Investment Advisors LLC lifted its holdings in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Robert W. Baird raised their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Guggenheim assumed coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price on the stock. Barclays dropped their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. TD Cowen raised their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Finally, The Goldman Sachs Group raised their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the sale, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the transaction, the insider now directly owns 78,996 shares in the company, valued at $3,154,310.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the transaction, the senior vice president now owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The disclosure for this sale can be found here. Insiders sold 15,125 shares of company stock valued at $664,784 over the last ninety days. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Trading Down 3.2 %

Shares of Twist Bioscience stock opened at $46.44 on Monday. The business’s fifty day simple moving average is $47.27 and its 200 day simple moving average is $43.08. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The firm has a market capitalization of $2.70 billion, a P/E ratio of -13.82 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the prior year, the business earned ($1.01) earnings per share. The business’s quarterly revenue was up 27.7% compared to the same quarter last year. Analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.